A randomized, multi-centre, efficacy evaluation of PI-88 in patients with hepatocellular carcinoma after hepatectomy - a phase II study

Trial Profile

A randomized, multi-centre, efficacy evaluation of PI-88 in patients with hepatocellular carcinoma after hepatectomy - a phase II study

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2009

At a glance

  • Drugs Muparfostat (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Progen Pharmaceuticals Limited
  • Most Recent Events

    • 16 Apr 2007 Final results of stage 1 reported in a Progen media release.
    • 16 Apr 2007 Status changed from in progress to completed.
    • 15 Apr 2007 Results have been presented at EASL 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top